Clinical trials / NCT07029412
NCT07029412Phase 2Completed

Study to Evaluate Efficacy and Dose Response of Imapextide (STEADI)

Study sponsor: MBX Biosciences

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov recordCSV export · Pro
Primary completion2026-04-18Actual
Enrollment · participants20Actual
Source updated2026-07-02Last update listed in the registry record
Version history

Changes to this trial

Last 12 months
Pro unlocks the full available history and CSV export. View Pro features

· 5 fields changed

Participant count type changed

− Before

Estimated

+ After

Actual

Enrollment · participant count changed

− Before

10 participants (planned)

+ After

20 participants (actual)

Completion date type changed

− Before

Estimated

+ After

Actual

Primary completion date changed

− Before

22 Dec 2025

+ After

18 Apr 2026

Recruitment status changed

− Before

Recruiting

+ After

Completed

Check registry source

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Compare wording
− Before

Measure: Changes from baseline to post-treatment in glucose nadir during a standardized MMTT following 2 different dose levels of MBX 1416.

+ After

Measure: Changes from baseline to post-treatment in glucose nadir during a standardized MMTT following different dose levels of MBX 1416.

Check registry source

· 1 field changed

Recruitment status changed

− Before

Not yet recruiting

+ After

Recruiting

Check registry source